Literature DB >> 21084155

Intraoperative ultrasound score to predict recurrent hepatocellular carcinoma after radical treatments.

Roberto Santambrogio1, Mara Costa, Daniela Strada, Emanuela Bertolini, Massimo Zuin, Matteo Barabino, Enrico Opocher.   

Abstract

Despite the high complete necrosis rate of radio-frequency ablation (RFA) or the complete removal following curative hepatic resection (HR), recurrent hepatocellular carcinoma (HCC) remains a significant problem. The aim of the study is to identify some intraoperative ultrasound (IOUS) patterns, predicting intrahepatic recurrences. From January 1997 to July 2009, 410 patients with HCC were treated (162 HR and 248 RFA through a surgical access). All patients were submitted to IOUS examination: 148 IOUS were performed during the laparotomic access while 262 IOUS were performed during the laparoscopic access. Primary HCC was classified according to diameter, HCC pattern (nodular or infiltrative), echogenicity (hyper- or hypo-echoic), echotexture (homogeneous or inhomogeneous), capsular invasion, mosaic pattern, nodule in nodule aspect and infiltration of portal vessels. Number of HCC nodules was also considered. Multivariate analysis (Cox model) was performed to determine features associated with recurrent HCC using IOUS patterns that independently predicted recurrent HCC, a IOUS score was developed. The patients were followed for 3-127 months, (median follow-up: 21.5 months). In 220 patients (54%), intrahepatic recurrences occurred. In 155 patients (38%), distant intrahepatic recurrences arose in different segments at the primary tumor site. In 65 HCC cases (16%), local recurrences were found. At multivariate analysis, multiple nodules, HCC diameter (>20 mm), HCC pattern (infiltrative), hyperechoic nodule and portal infiltration were statistically significant for risk factor of intrahepatic recurrences. Therefore, a IOUS scoring system was calculated on the basis of multivariate analysis and identified three risk categories of patients: in group 1 recurrences occurred in 37%, group 2 in 46% and group 3 in 66% (p = 0.0001). IOUS is an accurate staging tool during "surgical" procedures. This study showed an added value of IOUS: it permitted to identify ultrasound patterns, which can predict the risk of HCC recurrences. The calculated IOUS score permits to intraoperatively evaluate the actual surgical choice and to program the best treatment strategies during the follow-up period.
Copyright © 2011 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21084155     DOI: 10.1016/j.ultrasmedbio.2010.10.007

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  4 in total

1.  Effect of Age (over 75 Years) on Postoperative Complications and Survival in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma.

Authors:  Roberto Santambrogio; Matteo Barabino; Giovanna Scifo; Mara Costa; Marco Giovenzana; Enrico Opocher
Journal:  J Gastrointest Surg       Date:  2017-01-12       Impact factor: 3.452

2.  Long-term outcome of laparoscopic ablation therapies for unresectable hepatocellular carcinoma: a single European center experience of 426 patients.

Authors:  Roberto Santambrogio; Matteo Barabino; Savino Bruno; Mara Costa; Andrea Pisani Ceretti; Maria Rachele Angiolini; Massimo Zuin; Franca Meloni; Enrico Opocher
Journal:  Surg Endosc       Date:  2015-08-15       Impact factor: 4.584

3.  Intraoperative abdominal ultrasound in oncologic imaging.

Authors:  Leonardo P Marcal; Madhavi Patnana; Priya Bhosale; Deepak G Bedi
Journal:  World J Radiol       Date:  2013-03-28

4.  Ultrasonogram of hepatocellular carcinoma is associated with outcome after radiofrequency ablation.

Authors:  Kosaku Moribata; Hideyuki Tamai; Naoki Shingaki; Yoshiyuki Mori; Tatsuya Shiraki; Shotaro Enomoto; Hisanobu Deguchi; Kazuki Ueda; Izumi Inoue; Takao Maekita; Mikitaka Iguchi; Masao Ichinose
Journal:  World J Hepatol       Date:  2012-12-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.